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The development of acute nonlymphocytic leukemia (ANLL) after 
long-term cytotoxic chemotherapy and/or radiation therapy has been 
reported with increasing frequency during the past 15 years. Most 
earlier cases were observed in patients with seemingly related hema¬ 
tologic disorders such as Hodgkin's disease (15), multiple myeloma 
(81), and polycythemia vera (110). However, reports of the development 
of acute leukemia among patients whose primary cancers did not involve 
the bone marrow and in malignancies not previously associated with the 
development of leukemia, such as brain (19), lung (31, 91) and breast 
(22) cancer, malignant melanoma (44), and ovarian carcinoma (4, 24, 
26, 38, 43, 46, 112, 89, 48, 57, 63, 66, 36, 67, 70, 73, 76, 85) were 
disturbing. In. all these cases the primary mode of treatment involved 
single or multiple agent chemotherapy and/or radiation therapy. 
The development ot ANLL in these patients has led to the specula¬ 
tion that this condition is a post-therapeutic complication of the 
intensive therapy administered, rather than an end development of the 
natural history of the initial malignancy. Reports of ANLL developing 
in chronically immunosuppressed patients treated with cytotoxic agents 
for connective tissue diseases (19, 79, 70), in renal transplantation 
patients (41) and other non-neoplastic diseases (96, 50, 75, 68, 111) 
further supports this view. 
Although radiation therapy has been associated with leukemogenesis, 
chemotherapy with alkylating agents appears to carry a higher risk of 
development of ANLL than is otherwise expected. The mechanism of 
action of these drugs at the cellular level is thought to resemble 

2. 
that of irradiation, which has been proven to be a potent leukemogen. 
Alkylating agents have proved particularly effective in the 
treatment of ovarian cancer and have been used more extensively in 
the management of this disease than any other agents. Therefore, 
ovarian cancer patients would appear to incur a particularly high 
risk of post-therapeutic acute leukemia. 

3. 
Materials and Methods 
Between 1964 and 1971, 79 patients with ovarian carcinoma were 
treated at Yale-New Haven Hospital with a combination of surgery, 
radiotherapy, and chemotherapy. Tumors were staged and classified 
according to the guidelines of the International Federation of 
Gynecology and Obstetrics (see Table 1). Uracil mustard, an alkylating 
agent, and 5-fluorouracil (5-FU), a pyrimidine antimetabolite, were 
chosen as chemotherapeutic agents because of their proven synergistic 
activity against various neoplasms in laboratory studies with mice. 
The protocol at that time consisted of 1 mg/kg/day of uracil mustard 
as a continual oral dose and 5-FU at a dose of 5 mg/kg intravenously 
for 5 days, every 4 weeks. Hematologic toxicity was followed with 
weekly white blood cell counts (WBC) with differential, hemoglobin 
levels, hematocrit levels and platelet counts. If leukopenia or 
3 
thrombocytopenia developed, as evidenced by a WBC lower than 4,000/mm 
3 
or a platelet count lower than 100,000/mm , the chemotherapy was dis¬ 
continued until these signs of bone marrow function improved. Anemia 
was treated with oral iron medication and blood transfusions if neces¬ 
sary. Therapy was also discontinued during any infectious processes. 
The patients' progress was assessed in the gynecological chemotherapy 
clinic by physical examination and laboratory studies which included 
liver function tests, blood urea nitrogen and creatinine, haptoglobin 
levels, and chest X-rays, if indicated. 
An objective response was defined as a complete disappearance 
of the tumor mass as measured by inspection, palpation, or roentgeno¬ 
graphy, and a disappearance of ascites, both sustained for a three 
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month period during which no new tumor lesions developed. A partial 
response consisted of a decrease in the size of the tumor over a 3 
month period or control of serous effusions for 3 months or longer. 
A nonresponse was defined as failure to effect a response on the basis 
of the therapy administered according to the planned regimen during 
at least a three-month period. 
In this group of 79 patients, 16 responders survived longer than 
36 months, and of these, three developed ANLL. Two patients received 
multiple courses of anti-leukemic chemotherapy, but a remission was not 
obtained in either patient. Patient 1 was treated with various combi¬ 
nations of methotrexate, leukovorin, doxorubiun, cyclophosphamide, 
vincristine, ara-C, 6-mercaptopurine, azauridine, TZT, and pyrazofurin. 
Patient 2 was treated with daunomycin and ara-C. The third patient 
received only palliative treatment for pancytopenias and infections. 
Case reports of these three patients follow. 
PATIENT 1 
Mrs. A.S. was a nulliparous 48 year old white female, with a 
history of menometrorrhagia since 1951. Between 1964 and 1969 she 
had been treated with birth control pills. In June, 1969, the patient 
developed continuous vaginal bleeding with heavy clots and lower 
abdominal pains. Pelvic examination showed a uterus twice normal 
size and a mass in the left adnexa measuring about 10 cm. in diameter. 
The right adnexa was unremarkable. In October, 1969, an endometrial 
biopsy showed adenomatous hyperplasia. An intravenous pyelogram 
showed a rounded soft tissue mass in the left pelvis pressing on the 
bladder. On November 10, 1969, she underwent exploratory laparotomy. 
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The uterus appeared normal. The left ovary was found to be replaced by 
a multilocular cystic mass measuring 8.5 x 10 cm. The right ovary 
was also multiloculated and filled with chocolate-colored fluid. There 
were no ascites or implants in the peritoneal cavity. The omentum 
was normal and there was no evidence of liver metastases. Histologic 
examination of the left mass by frozen section showed a papillary 
adenocarcinoma of the ovary. A total abdominal hysterectomy and 
bilateral-salpingo-oophorectomy were performed. The pathology report 
confirmed the diagnosis of ovarian carcinoma grade 1 and also showed 
an invasive adenocarcinoma of the endometrium. The ovarian cancer 
involved the left ovary and the left fallopian tube; the right ovary 
was free of disease. The tumor was thus a stage IIA papillary adeno¬ 
carcinoma of the ovary; the endometrial cancer was stage IA, grade 1. 
Following recovery from the surgery, the patient was treated 
with radiation therapy. She received 1,200 rads to the whole abdomen 
and an additional 2,800 rads to the pelvis between November 19 and 
December 22. This course of therapy was complicated by severe diarrhea, 
treated with Lomotil, and by a dry desquamation of the skin of the 
abdomen and the posterior buttocks, which resolved upon cessation of 
therapy. Subsequent pelvic examination showed no evidence of either 
abdominal or pelvic masses. On January 14, 1970, a radium plaque 
with a total dose of 1,200 mgm hours was inserted vaginally for 33 
hours to prevent vaginal vault recurrence of the endometrial cancer. 
In February, 1970, the patient developed ascites and a diagnostic 
paracentesis was performed. Analysis of the fluid showed malignant 
cells consistent with adenocarcinoma. In March the patient was started 
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on chemotherapy with a combination of uracil mustard and 5-fluorouracil 
and also with Depo-Provera, 400 mg. per week by intramuscular injection 
During each five day course of 5-FU, the patient had diarrhea, which 
resolved after treatment. In October, 1970, pelvic examination re¬ 
vealed a 6 cm. mass at the apex of the vagina. However, this had 
regressed entirely by August, 1971, and the patient remained asympto¬ 
matic and free of disease for the remainder of treatment. 
In May, 1971, she developed a mild pancytopenia with a macrocytic 
anemia, Vitamin B12 and red cell folate levels were depressed. The 
3 
WBC was 4,100 cells/mm with a normal differential; the Hgb was 9.8 
3 
gm/dl, the Hct was 31.2%, and the platelet count was 80,000/mm . A 
work-up for a malabsorption syndrome was negative. Treatment with 
Vitamin B12, iron. Vitamin C, and multi-vitamins was begun, with 
improvement of the macrocytosis, but mild anemia persisted with the 
Hgb levels fluctuating between 11.7 and 13.0 gm/dl. 
Chemotherapy was continued uninterrupted for 33 months until 
December, 1972. The total dose of uracil mustard was 900 mgs. and 
3 
that of 5-FU was 71 gms. At the end of therapy the WBC was 4,500/mm 
with a normal differential; the Hgb was 11.7 gm/dl, the Hct was 36.7%, 
3 
and the platelet count was 150,000/mm . The patient was in good 
health without evidence of recurrence of either the ovarian or endo¬ 
metrial cancers; however she was lost to follow-up. 
In November, 1974, 23 months after completing chemotherapy, Mrs. 
S. experienced increasing shortness of breath, developed a cough with 
a white sputum, and had occasional chills. On physical examination 
she had a 0.4 cm. ulcerated lesion of the left chin. There were no 
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petechiae, purpura, lymphadenopathy, or pedal edema. The spleen was 
3 
not palpable. The WBC was 50,600 cells/mm with 35% blasts. The Hgb 
3 
was 9.5 gm/dl, the Hct was 35%, and the platelet count was 975,000/mm . 
She was admitted to Yale-New Haven Hospital for investigation with a 
provisional diagnosis of leukemia. 
Bone marrow aspirate showed a hypercellular marrow with 17% 
myeloid cells, 24% erythroid cells, and 45% myeloblasts. The erythroid 
elements showed a predominance of early basophilic forms with vacuoli¬ 
zation, binucleation, nuclear hyperlobulation, and megaloblastic forms. 
The myeloid:erythroid ratio was 1:1. A chromosomal study revealed a 
female karyotype with 45 chromosomes. All cells examined were abnormal, 
with chromosome no. 18 missing. The long arm of chromosome no. 3 
contained extra material which may have been the result of a translo¬ 
cation of some of chromosome no. 18. There was no Ph chromosome. A 
diagnosis of acute myelogenous leukemia was made. 
On November 25 antileukemia therapy with multiple agents was 
begun. There was never a remission and she expired six months later. 
At autopsy, the gastrointestinal tract exhibited multiple ulcerations. 
The liver and spleen were severely congested and were extensively 
involved with leukemic cells. The bone marrow was hypercellular, 
with marked hyperplasia of the myeloid series, mostly myeloblasts. 
There was no sign of recurrent ovarian disease. 
PATIENT 2 
Mrs. J.J. was a 43 year old nulliparous black female, who had 
had a history of occasional dysmenorrhea and lower abdominal pain 
since 1966. On physical examination in August 1969, an enlarged. 
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irregular uterus and a large right adnexal cystic mass were palpated. 
The left adnexa was unremarkable. A diagnosis of uterine leiomyoma 
was made, and upon an increase in the severity of symptoms, the patient 
was admitted to Yale-New Haven Hospital in November, 1969, for dilata¬ 
tion and curettage, pelvic examination under anesthesia and possible 
abdominal hysterectomy. 
On November 12, examination under anesthesia showed a right 
ovary approximately three times normal size; the left ovary could not 
be palpated, and the uterus was enlarged with a possible fibroid. An 
exploratory laparotomy was performed. Upon entering the abdominal 
cavity, a large amount of blood-stained fluid was found; the omentum 
was edematous, thickened, and somewhat nodular, although no definite 
metastatic nodules were discovered. The right ovary was surrounded 
by a large fungating mass which spread posteriorly to involve the 
posterior surface of the uterus and the cul-de-sac; the left ovary was 
enlarged and was covered with a fungating mass. The liver could not 
be palpated because of adhesions in the right upper quadrant. The 
para-aortic nodes were not enlarged. A biopsy of the right ovary was 
taken, and the abdomen was closed without further resection. The 
pathology report showed a low grade papillary serous cystadenocarcinoma. 
Between November 24 and December 30 the patient received 2,000 
rads to the whole abdomen and an additional 1,800 rads to the pelvis. 
Initially she tolerated the treatment well, but in mid-December increas¬ 
ing abdominal pain developed and she became anemic. The pelvic mass, 
which previously was barely palpable abdominally, now showed a rapid 
increase in size, filling the entire lower abdomen and rising up to 
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about two finger breadths above the umbilicus. Mrs. J. was seen in 
the emergency room several times in late December because of lower 
abdominal pain and treated with analgesics. On December 31, she was 
admitted to the hospital for investigation. An intravenous pyelogram 
showed a soft tissue mass in the pelvis and bilateral partial obstruc¬ 
tion of the ureters. She was discharged January 7 and readmitted on 
January 28, complaining of anorexia, increased abdominal pain and fever 
Intermittent episodes of diarrhea began on this admission and resolved 
with Lomotil. In February the patient developed a Klebsiella sepsis. 
Chest X-ray on February 14 showed a left lower lobe pneumonia with 
atelectasis and a left pleural effusion. Treatment with Gentamycin 
resulted in improvement. 
A three-way abdominal film also taken on the 14th showed multiple 
air fluid levels in the large and small bowel. These findings were 
believed to be evidence of either a paralytic ileus secondary to 
abdominal carcinomatosis or a distal large bowel obstruction. 
On February 27, the patient underwent a second exploratory lapa¬ 
rotomy. Examination of the abdominal cavity revealed two large ovarian 
masses adherent to loops of the small bowel and the sigmoid colon, 
all of which were adherent anteriorly to the bladder. The right ovary 
measured 8x4 cm.; the left ovary was 5.5 cm. in diameter. A 
bilateral salpingo-oophorectomy and subtotal omentectomy were performed 
However, remnants of tumor were left on the sigmoid colon, near the 
area of the cecum on the right, and between the uterus and the bladder 
anteriorly; these were all clipped. Minimal nodularity was noted in 
the cul-de-sac on the back of the uterus. Histologic examination 
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confirmed the previous diagnosis of papillary serous cystadenocarcinoma 
of the ovary (Stage III). Postoperatively, Mrs. J. did well except 
for brief episodes of diarrhea, which resolved spontaneously. 
Chemotherapy for the nonresectable disease was begun on April 6, 
1970, with a combination of uracil mustard and 5-fluorouracil. The 
3 
WBC was 8,700 cell/mm with a normal differential, the Hgb was 8.5 gm/ 
2 
dl, and the platelet count was 80,000/mm . In October, a pelvic 
examination was remarkable in revealing an irregular, firm, mobile, 
3 cm. mass to the right of the uterus, however, by December the mass 
had regressed entirely. Therapy was complicated by the onset of 
constant diarrhea, with up to 6 bowel movements per day. Sigmoido¬ 
scopy and a barium enema revealed extensive colitis as a consequence 
of the original radiation therapy. The diarrhea was successfully 
treated with Paregoric and Lomotil. At the same time the patient's 
hematocrit decreased to 21%, and she received three units of PRBC. 
On July 6, she had another episode of anemia with a Hct of 19% and 
received two units of PRBC. She tolerated the remainder of the 
chemotherapy for the ovarian cancer well without any other somatic 
complaints or severe hematologic abnormalities. 
All subsequent examinations, liver studies, and intravenous pyelo- 
grams showed no evidence of recurrent disease. The patient refused 
second-look surgery. Therapy continued with only brief interruptions 
until June, 1975, after 62 months; a total dosage of uracil mustard 
1,700 mgs. and 5-fluorouracil 85.8 gms. had been administered. At 
3 
this time, the WBC was 4,500/mm with a normal differential count. 




170,000/mm . Mrs. J. was active and in good health during the follow¬ 
ing 17 months, but was lost to follow-up at the end of this period. 
In October, 1976, she began to complain of bleeding of the gums. 
Routine hematologic studies in November showed that the WBC was 5,800/ 
O 
min with 8% blasts; the Hct was 26% and the platelet count was 31,000/ 
mm . Physical examination was remarkable for ecchymoses over the legs 
and petechiae over the ankles. The spleen was slightly enlarged with 
no lymphadenopathy. Bone marrow aspirate revealed a 4+ cellular 
marrow with 50% blasts that had monocytoid features, and 35% erythroid 
elements, 15% of which were early precursors, showing marked atypia 
of development with megaloblastic changes and many binucleated and 
trinucleated forms. The myeloid:erythroid ratio was 5:3. A diagnosis 
of acute myelomonoblastic leukemia with a marked dyserythropoiesis 
was made. The patient was admitted for treatment on November 4th and 
received three courses of chemotherapy with daunomycin and ara-C 
without benefit. She expired six months later. An autopsy was not 
performed. There had been no clinical evidence of recurrent ovarian 
cancer. 
PATIENT 3 
Mrs. J.M. was a 51 year old white female, gravida 2, para 2, with 
a history of recurrent lower abdominal pain beginning September, 1969 
and a tentative diagnosis of diverticulitis. On January 12, 1970, 
she noticed right lower abdominal swelling. She was admitted to 
Widham Community Memorial Hospital in Connecticut for evaluation. On 
physical examination there was a definite, non-tender, cystic mass in 
the right lower quadrant. Pelvic examination showed a fullness in 
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the anterior vaginal vault. Ballotment of the cervix was associated 
with anterior motion of the entire mass. An abdominal film showed a 
large pelvic mass. A barium enema was negative for diverticulitis 
and showed that the mass did not involve the colon. On January 15, 
the patient underwent sigmoidoscopy, pelvic examination under anes¬ 
thesia, and dilatation and curettage. 
On January 19, an exploratory laparotomy was performed. A large 
mass, replacing the right ovary and involving the right fallopian 
tube, the left fallopian tube, and the left ovary was found. Implants 
of tumor covered the gastrointestinal tract, which was adherent to the 
pelvis. A total abdominal hysterectomy and bilateral salpingo-oopho- 
rectomy were performed. Histology showed an adenocarcinoma of the 
ovary with both glandular and squamous elements, consistent with the 
endometroid pattern of ovarian cancer. A diagnosis of stage III 
adenocarcinoma of the ovary was made. 
After a slow and uneventful recovery, the patient received radio¬ 
therapy for the residual cancer. Between March 2 and April 4, 1970, 
2,000 rads were administered to the whole abdomen and an additional 
1,875 rads to the pelvis. She tolerated the treatment well except for 
several thrombocytopenic and leukopenic episodes which were resolved 
by brief cessations of therapy. The patient also experienced mild 
nausea and diarrhea, which was successfully treated with Compazine 
and Lomotil. Physical and pelvic examinations at the end of treat¬ 
ment were negative for tumor. 
On August 24, an ill-defined mass in the right mid-abdomen was 
palpated abdominally, but not on pelvic examination. This was assumed 

13. 
to be a recurrence of the ovarian carcinoma, and the patient was 
started on chemotherapy. 
As with the previous two patients, Mrs. M. received 5-fluorouracil 
for five consecutive days each month, but uracil mustard was adminis¬ 
tered at a dosage of 1 mg. every other day, instead of 1 mg. every 
day because of frequent leukopenic episodes. By March, 1971, there 
was no evidence of the abdominal mass, and the patient remained free 
of recurrent disease. In September, 1971, leukopenia developed and 
the dose of uracil mustard was changed to 1 mg. every third day. The 
leukopenia persisted and thrombocytopenia developed and all therapy was 
discontinued in April, 1973. Total treatment time was 32 months, with 
a total uracil mustard dose of 348 mgs. and 5-FU a total dose of 24 
gms. 
The patient was in excellent health for the next four and a 
half years, although she had persistent anemia and a slight leukopenia. 
3 
The WBC was 4,200/mm , with a normal differential; the Hct was 35% 
and the platelet count was within normal limits. In late December, 
1977, the patient began to experience mild dyspneic episodes while 
walking. A routine hematologic study revealed a pancytopenia: the 
3 
WBC was 1,900/mm , the Hct was 27.7% and the platelet count was 120,000/ 
3 
mm . A bone marrow aspirate in January showed a markedly hypocellular 
marrow with 50% blasts and 20% lymphoblasts. There were a few scat¬ 
tered erythroid precursors which exhibited megaloblastic changes. This 
was compatible with a myelodysplastic syndrome or an evolving acute 
myeloblastic leukemia; however, because of her age and her previous 
history of radiotherapy and long-term chemotherapy, the patient was 
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followed closely and treated symptomatically with intermittent red 
blood cell and platelet transfusions rather than receiving more ag¬ 
gressive treatment. A chromosome analysis showed a normal karyotype. 
During the next five months, there was a slow progression of her 
disease. She became increasingly more symptomatic as evidenced by 
fatigue, pallor, bony pain, and small, sporadic ecchymoses. The bone 
marrow remained severely hypocellular, and the patient became in¬ 
creasingly dependent on platelet transfusions. There was a slow, 
progressive development of her myeloblastic leukemia into an acute 
monocytic type by the end of March. The patient died June 1978 after 
being lost to follow-up. An autopsy was not performed but at the 
last physical examination she was thought to be free of recurrent 
ovarian disease. 
Results 
In this group of 79 patients treated for advanced ovarian cancer, 
16 (20.25%) survived more than three years after their initial diagno¬ 
sis. Eight of these died of recurrent disease at 39, 41, 48, 51, 68, 
96, 105 and 108 months respectively. Two patients died of coronary 
artery thrombosis at 84 and 120 months. A third died of unknown 
causes at age 83 after a survival of 96 months. She had a laparotomy 
at age 80 and she was free of ovarian cancer. Two patients are alive 
120 and 156 months after diagnosis; one of these had a stage IIB 
carcinoma of the ovary, the other a stage III carcinoma of low grade. 
The remaining three patients (18.75%) developed ANLL 56, 79, and 84 
months after chemotherapy was started. These three patients represent 
3.75% of the total group undergoing treatment; a significant percentage 
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when compared to the number of expected cases of ANLL in the general 
population which is 2.2 cases per 100,000 (99). 
All 16 patients were initially treated surgically, then received 
radiation therapy and chemotherapy with uracil mustard and 5-FU; three 
patients were unresponsive to these agents and received chlorambucil 
and vinblastine. The development of acute leukemia was not related 
to the cumulative dose of uracil mustard administered (see Table 2), 
as all three patients appeared to be evenly distributed within a dose 
range of 348 mgs. and 1700 mgs. 
Among the three patients who developed leukemia only the first 
appeared to have disease amenable to optimal surgical resection; the 
other two had widely disseminated unresectable disease at the time of 
diagnosis. All three received radiation therapy to the abdomen and 
pelvis and in addition the first patient received radium therapy. 
Radiation doses ranged from 3800R to 4000R. Episodes of cytopenia 
were common during the course of this treatment, with the development 
of thrombocytopenia in patient 1, anemia in patient 2, and both leuko¬ 
penia and thrombocytopenia in patient 3. However, all abnormalities 
were rapidly reversible with brief cessations of therapy. Exposure 
to radiation did not appear to influence the interval prior to leukemia 
development; all three received almost identical doses. 
Chemotherapy with uracil mustard and 5-FU was begun for the 
treatment of unresectable disease and was maintained for a period 
ranging from 32 to 62 months (mean 42.3 months). The total dose of 
uracil mustard ranged from 348 mgs. to 1700 mgs.; and the total dose 
of 5-FU ranged from 24 gms. to 85.5 gms. Episodes of cytopenias 
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occurred in all three patients throughout treatment although none 
developed pancytopenia. In the first two cases cessation of therapy 
brought about resolution of these abnormalities but in the third case 
leukopenic episodes were frequent and persistent despite adjustment 
of the dose of uracil mustard. A lack of objective evidence of recur¬ 
rent disease in all patients and the onset of persistent leukopenia 
and thrombocytopenia in the third patient led to discontinuation of 
therapy. Second-look laparotomies were not performed. 
ANLL developed after a latent period of 56, 79, and 86 months 
respectively (mean 73.6 months). The first patient had normal hemato¬ 
logic parameters during the time she maintained follow-up. She pre¬ 
sented with leukocytosis, and increased platelet count, and a mild 
anemia. A chromosomal study showed hypodipoidy. She received in¬ 
tensive anti-leukemic therapy with multiple agents but was unresponsive 
A preleukemic syndrome also appeared to be absent in the second patient 
She presented with anemia, thrombocytopenia, and a normal WBC. This 
patient had the shortest latent period and received the largest dose 
of uracil mustard. A chromosomal study was not performed. She under¬ 
went three unsuccessful attempts at induction of a remission. Bone 
marrow studies in these two cases showed similar patterns. Both were 
highly hypercellular with bizarre, immature granulocytic forms and 
megaloblastoid changes. Megakaryocytes were abnormal and severely 
depleted. There was marked dyserythropoiesis with rare mature ery- 
throid elements, many erythroblasts, and ringed sideroblasts. Death 
occurred five and seven months after leukemia developed, respectively. 
At autopsy the first patient was free of ovarian cancer; the second 
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had no evidence of disease at the last physical examination. 
The third patient developed a persistent anemia 13 months prior 
to the onset of acute leukemia although she did not become pancytopenic 
until 1 month before diagnosis. This patient received the lowest dose 
of uracil mustard and had the longest latent period. However, she 
experienced the greatest amount of marrow damage as evidenced by 
persistent leukopenia throughout treatment and by the history of anemia 
before the onset of leukemia. A chromosomal study showed a normal 
karyotype. Initial bone marrow analysis showed severe hypocellularity 
and erythroid hypoplasia consistent with a myelodysplastic syndrome, 
but without enough cellular differentiation to establish an accurate 
diagnosis. Over the next three months more definite changes in the 
marrow consistent with acute myelogenous leukemia began to appear, 
until finally all abnormalities were consistent with the diagnosis of 
acute myelomonocytic leukemia. This patient did not receive antileukemic 
therapy. Death occurred seven months after the diagnosis of leukemia. 
An autopsy was not performed, but at the last physical examination 




The earliest report of the development of acute leukemia in a 
patient with ovarian cancer appeared in 1962. The patient was one of 
14 with a primary malignancy that was treated with extensive radiation 
therapy, and who developed leukemia following a long disease-free 
interval (26). 
Reports implicating alkylating agents in the development of acute 
leukemia following therapy for ovarian cancer began appearing in 1970. 
To date a total of 54 patients (including the three presented here), 
have been reported (see Table 2). Of these, 26 were staged at the 
time of diagnosis: 2 presented in stage IV disease, 18 in stage III, 
2 in stage IIA, and one each in stages la, lb, and Ic. Of the re¬ 
maining 28, five were reported to have disease outside the pelvis at 
the time of surgery although they were not staged; in 23 this informa¬ 
tion was not provided although the case histories were consistent 
with advanced disease. 
Twenty-four patients (44.44%) did not receive radiation therapy. 
They were treated with one or more alkylating agents or with one 
alkylating agent and an antimetabolite. The duration of therapy in 
this group ranged from 4 months to 90 months. The most frequent 
single agents used were melphalan (phenylalanine mustard) (11 patients), 
leukeran (chlorambucil) (9 patients), treosulfan (8 patients), thiotepa 
(3 patients), and cytoxan (cyclophospamide) (1 patient). The two 
non-alkylating agents used were: methotrexate and 5-FU. Six patients 
were treated with a combination of uracil mustard and 5-FU; nine 
others received various combinations of the above agents. Thus, the 
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leukemogenic affect of Irradiation cannot explain the development of 
ANLL in almost half of the patients who received prolonged cytotoxic 
agent therapy. 
In addition to chemotherapy, twenty-four patients (44.44%) re¬ 
ceived radiation therapy which consisted of irradiating the whole 
32 
abdomen and/or the pelvis, radium treatments or P therapy. Two 
patients (3.70%) received irradiation only. Three patients received 
chemotherapy but a history of radiation therapy was not documented. 
In one patient therapy was not specified. Although the relative sig¬ 
nificance of irradiation in these patients was not closely analyzed, 
in two groups of patients it did not appear to be a major leukemogenic 
factor. In the report by Reimer et al, all 13 cases of ANLL developed 
in the group treated with chemotherapy (76) . In the report by Pedersen- 
Bjegaard et al, of 553 patients treated for ovarian cancer, 274 re¬ 
ceived radiation therapy and only 2 of these developed ANLL in contrast 
to five patients in the remaining 279 patients treated with chemotherapy. 
However, these two patients had the shortest latent period from the 
initiation of chemotherapy to the development of leukemia (67). 
Three patients (76, 111) were treated with surgery, radiation 
therapy and chemotherapy with uracil mustard and 5-FU. The duration 
of therapy and total dose received were not reported. In the first 
patient a detailed history was not provided. The latent periods were 
26, 60 and 84 months respectively (mean 56.6 months). The second and 
third patient were pancytopenic for an undetermined period of time 
before the diagnosis of ANLL. A chromosomal study in the second 
patient was abnormal showing hypodiploidy. These two patients received 
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antileukemic therapy and achieved partial remission. Survival after 
the diagnosis of leukemia was 6 and 7 months, and considerably longer 
than other patients with ANLL. The cause of death was not reported, 
but at autopsy there was no evidence of either leukemia or ovarian 
carcinoma. 
Eight patients underwent a second laparotomy at some point 
during their treatment; two of these were necessary to relieve an 
ileus (89) and a small bowel obstruction (48), and six were diagnostic 
second look procedures (24, 63, 76). In the two cases where surgery 
was required, the first patient had not received chemotherapy for the 
previous 16 months because an earlier negative laparotomy performed to 
relieve an ileus was negative for ovarian tumor. At the time of the 
second surgery she was found to have widespread disease and was re¬ 
started on chemotherapy. In the second patient, the obstruction was 
secondary to adhesions. Although there was no evidence of cancer at 
the time of the operation, the patient was restarted on chemotherapy 
six months later. Of the six patients who underwent elective surgery, 
all were free of disease; in three chemotherapy was discontinued. 
The clinical course of secondary ANLL in most patients was often 
preceded by frequent episodes of pancytopenias and cytopenias (97.7%). 
Hematologic abnormalities developed in 42 patients prior to the 
development of leukemia. Thirty-five were pancytopenic for a period 
ranging from one to 36 months. Seven experienced varying degrees of 
cytopenias but did not develop pancytopenia. In 11 patients this 
information was not provided. All attempts at treatment with testos¬ 
terone and corticosteroids were unsuccessful. These symptoms have 
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been previously reported to be characteristic of preleukemic states 
(44, 15, 81). 
The latent period from the beginning of chemotherapy to the 
diagnosis of ANLL ranged from 19 months to 114 months, with a mean of 
52.8 months. This interval was slightly longer for those patients who 
received chemotherapy only (mean 55.6 months), as opposed to those 
who received both chemotherapy and radiation therapy (mean 52.1 months). 
A latent time of four to five years after the start of chemotherapy 
corresponds closely to the findings in other series of patients with 
ovarian cancer (67, 76), lung cancer (95), multiple myeloma (79) 
and Hodgkin’s disease (80) who have developed ANLL. 
Acute myeloid leukemia was the most common type of leukemia (26 
cases), followed by acute myelomonocytic and erythroleukemia which 
developed with equal frequency (eight cases each). One patient 
presented with a myeloproliferative syndrome which later developed 
into erythroleukemia; another presented with a myelodysplastic syn¬ 
drome which later developed into acute myeloid and then into acute 
myelomonocytic leukemia. There was one case of acute undifferentiated 
leukemia. 
Chromosome analysis was reported in 12 cases. Nine of these were 
abnormal, with hypodiploidy the most common aberration. Three karyo¬ 
types were normal (36, patient 54, Table 2). These three patients 
presented with a preleukemic syndrome. These cytogenetic studies are 
consistent with previous reports of a very high incidence of karyo¬ 
type abnormalities in secondary ANLL (15, 67, 80). 
Bone marrow findings were similar in most patients. The majority 
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were markedly hypercellular, although a few were hypocellular and two 
patients had myelofibrosis. There was a predominance of myeloblasts, 
promyelocytes, or myelomonocytes, with a severe left shift in myelo¬ 
cytic differentiation. Dyserythropoiesis was a common finding with 
hyperplasia and megaloblastoid changes of the erythroid elements. 
Ringed sideroblasts were usually present. 
Secondary ANLL seems to a great extent to be refractory to 
therapy, both in patients with previous ovarian cancer and in patients 
with other primary tumors. Only a few brief remissions have been 
described (15, 36, 57, 67, 81, 92). However, in most of these cases, 
the antileukemic therapy administered was insufficient for treatment 
of ANLL due to initial diagnostic problems in some patients and to 
the rapid course of the disease in others (67). Of the 27 patients 
treated, only three achieved complete remission (63, 112), four had 
partial remissions (48, 73, 112), and two were unresponsive but alive 
with progressive disease at one and two months after diagnosis (67). 
Twenty-two patients were not treated; two were alive at one month and 
seven months after diagnosis. In four patients the course after 
diagnosis was not reported. 
Post-mortem examinations were performed in 32 patients. Thirty 
had extensive dissemination of leukemia; 22 of these were free of 
ovarian disease. Of those not autopsied, four had no clinical evidence 
of disease at the time of the last physical examination; five were 
alive at the time of report and were free of ovarian disease. 
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Ovarian Cancer Management 
Ovarian carcinoma, though taking second place to endometrial 
carcinoma in frequency, remains the one gynecologic malignancy fre¬ 
quently not amenable to successful therapy. The therapeutic manage¬ 
ment of this disease has changed greatly in the last 20 years. The 
most significant factor was the realization that effective treatment 
required precise and accurate staging. Such staging can only be done 
by adequate exploration of the whole abdominal cavity, particularly 
the surface of the liver, the undersurfaces of the diaphragm, the 
paracolic gutters and the retroperitoneal nodes. Prior to 1965 these 
regions were frequently not explored and the extent of the disease was 
underestimated. The routine use of omentectomy also led to more 
accurate staging as the cancer frequently showed microscopic or small 
nodular involvement of the omentum. Such understaging explained the 
frequently found poor prognosis of apparently early disease. 
Concurrently with more accurate staging came the realization that 
patients with bulk disease remaining after surgery responded poorly to 
postoperative radiation. The chemotherapy agents used in the leukemias 
and lymphomas began to be used in solid tumors and patients with ovarian 
carcinoma were found to show response (104A). This led to clinical 
trials using alkylating agents in ovarian carcinoma. Phenylalanine 
mustard at M.D. Anderson, cytoxan at the Mayo clinic, and chlorambucil 
in London and New York were found to have very similar response rates. 
Palliation in advanced disease was shown to be possible and although 
little prolongation of life was achieved, tumor masses decreased in 
size and serous effusions resolved, frequently for many months. 
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Concurrently with the introduction of chemotherapy and the 
realization of the prognostic significance of bulk tumor, came the 
treatment practice of removing as much tumor as possible, a debulking 
procedure. All possible tumor is removed by oophorectomy, hysterec¬ 
tomy, omentectomy, and if necessary bowel resection so that the least 
possible amount of tumor is left to be treated by the chemotherapy 
(12A). Because patients who have all disease removed or who have 
only minimal disease left do better and live longer than those in 
whom bulk disease is left, the procedure of surgical debulking has 
become standard practice. 
It was against the background of the use of single agent chemo¬ 
therapy that the use of uracil mustard and 5-FU (UMFU) was introduced 
in 1964 as one of the first combination regimens in ovarian cancer. 
Combination drugs appeared to be more effective in lymphoid neoplasms 
and Booth and Sartorelli (11) had demonstrated a synergism between 
these agents in experimental sarcomas. 
UMFU had provided a response rate similar to alkylating single 
agent chemotherapy but no prolonged survival in the dose regimen used. 
There is no record of uracil mustard having been tried as a single 
agent in ovarian carcinoma, particularly with an intermittent dose 
schedule. 
The trial continued until 1970. At that time adriamycin became 
available and its use in combination with cytoxan and other agents 
appeared more promising than UMFU. Since then, platinum, hexamethyl- 
melamine, and adriamycin in combination with alkylating agents have 




The incidence of acute granulocytic leukemia and its variants 
in the general population in the United States has been shown to be 
2.2 cases per 100,000 persons per year (99). Since the advent of 
intensive therapy, the development of ANLL in ovarian carcinoma has 
been shown to be occurring with greater than expected frequency. 
Estimates of the actual frequency in these patients is not yet pos¬ 
sible because of the relatively small number of case reports (17). 
It was initially thought that the increased complication of 
secondary ANLL after treatment for a different primary malignancy 
was a consequence of the increased numbers of long-term survivors 
that resulted from successful therapy (36, 112); prolonged survival 
in these patients unmasking a natural tendency to develop another 
malignancy (46). The development of acute leukemia in hematologic 
disorders which originally involved the bone marrow, such as multiple 
myeloma, Hodgkin's disease, Waldenstrom's macroglobulenemia, and 
chronic lymphocytic leukemia lent evidence to the suspicion that 
acute leukemia may have been a natural, although late manifestation 
of these disorders, rare until a few years ago (44, 15, 98). However, 
the appearance of ANLL in patients with solid tumors and in immuno- 
suppressed patients made this supposition unlikely (17). Specifically, 
the association of ovarian carcinoma and acute leukemia is very rare 
(43). This disease has not been known to evolve as part of the 
natural history of ovarian cancer and epidemiologic studies have not 
suggested any special association between the two (76). 
In the most comprehensive series to date of patients with ANLL 
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following ovarian cancer, Reimer et al could not demonstrate an in¬ 
creased incidence of acute leukemia in a historical control group. 
These patients had ovarian cancer which was treated between the years 
1935 and 1972. The authors concluded that there was no evidence of 
an "inherent" risk of leukemia in patients with ovarian disease (76). 
The question also arises that the leukemia may be a part of the natural 
history of the disease, specifically associated with advanced cases. 
However, although the majority of patients who have received intensive 
therapy have had advanced widespread disease, the patients in the 
Reimer study were presumed to be in the early stages (76). In addi¬ 
tion three cases of ANLL were reported by Pederson-Bjergaard et al in 
patients with Stage I disease (67); two other patients (24, and one 
of the present cases - No. 52) were in stage IIA. The possibility of 
a chance association cannot be ignored, however, there is mounting 
evidence that suggests a relationship exists between the use of cyto¬ 
toxic drugs and the development of leukemia in these patients. 
It is known that these agents, while allowing control of the 
primary cancer, may permit or induce the growth of a second malignancy. 
As patients with ovarian carcinoma survive longer or are cured by 
the use of radiation and/or chemotherapy, the long-term complications 
of these methods of therapy may become more evident (17, 81). Fur¬ 
ther association between therapy and the development of ANLL can be 
seen in five earlier reports in addition to the present three cases 
(see Table 4). While the patients who developed leukemia in these 
reports represented a small fraction of the total sample of those 
undergoing treatment, they represented a significant percentage of 
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the long-term survivors. The most significant numbers appear among the 
three patients reported here who represent more than 3% of the total 
treated group, and 18,75% of the long-term survivors. In the report 
by Reimer et al, the 13 patients with leukemia represented 0.75% of 
the total sample, however, they showed a 36-fold increase in the 
incidence of secondary acute leukemia (13 cases observed compared with 
a theoretically predicted number of 0.36) compared with the general 
population (76). In the population followed by Pederson-Bjergaard, 
et al, the expected number of cases of acute leukemia was 0.004, they 
observed 7, a relative risk of 175 (67). 
A suspected dose effect relationship could not be confirmed in 
any of the previous studies, but in an earlier study by Einhorn 
leukemia developed in 4 of the 12 patients who received 800 mg. of 
melphalan (24). Only in the treatment of Hodgkin’s disease has it 
been shown that the risk of developing leukemia is a function of the 
intensity of therapy administered (44, 15). This risk is maximal 
when extensive irradiation is combined with polychemotherapy, the 
frequency of post-therapeutic leukemia being 29 times that of the 
general population (44, 15). Therefore, it would seem that aggressive¬ 
ness of therapy is an important factor in the development of ANLL 
although the exact relationship between dose and leukemia has not 
been clarified. 
The role of radiation therapy in this group of patients has yet 
to be defined. Irradiation has been suspect as a leukemogenic agent 
since 1925, when reports associating an increased incidence of acute 
leukemia in radiologists routinely exposed to radiation began to appear 

28. 
(101). The literature contains at least two dozen patients described 
in detail who have developed ANLL following treatment with radiation 
only, including patients who were treated with localized therapy (17, 
72). 
Studies on leukemia incidence and chromosomal analysis in humans 
after accidental, diagnostic, or therapeutic exposure to irradiation 
provided solid evidence that among these patients the risk of develop¬ 
ing leukemia was higher than in the rest of the population (10, 51). 
Data collected by the Atomic Bomb Casualty Commission show an increase 
in the incidence of leukemia in Japanese atomic bomb survivors in 
Hiroshima and Nagasaki (8, 9, 62). Studies of children exposed to 
radiation prenatally, for treatment of childhood carcinoma or during 
therapy for thymic enlargement and other medical ailments which were 
routinely treated with irradiation show that the number of deaths 
from leukemia exceeds that expected to occur in untreated children by 
a factor of 10 (55, 64, 88). Similarly, patients suffering from 
ankylosing spondylitis who were treated with multiple courses of 
localized radiation to the spinal column, and patients with polycy- 
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themia vera treated with radiation and P have a higher incidence 
of leukemia, up to 10 times that of untreated patients (13, 21, 61). 
Numerous other forms of cancer or benign disorders have been 
treated by radiotherapy alone (44). Several cases of secondary 
leukemia in these patients have been reported, occurring in four cases 
of Wilm's tumor (83), one cancer of the tongue (72), five cases of 
cancer of the larynx (45); all these patients had received local 
radiotherapy of up to 3,000 rads; in seven cases the acute leukemia 
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was myeloblastic and three others lymphoblastic. Survival was always 
less than six months (44) . In a study of pelvic irradiation. Smith 
documented 34 cases of acute leukemia (against a theoretically pre¬ 
dicted number of 33) out of 110,000 cervical cancers treated locally 
by radium or by local radiotherapy (doses of 1200 to 1500 rads.) In 
contrast, in the same study, out of more than 8,000 women in whom 
menopause was induced by radiotherapy, (a dose of 70 to 190 rads to 
the entire pelvis), 33 cases of acute leukemia developed while the 
theoretically predicted number was 13.5, an almost three-fold increase 
over the calculated incidence (90) . 
Radiotherapy appears to intervene in the leukemogenic process 
more by virtue of the extent of the irradiation than by the total 
dose delivered, since irradiation of the pelvis with less than 200 
rads multiplies by a factor of 3 the risk of acute leukemia, while 
300 to 1500 rads to the cervix does not increase the frequency (44). 
The same is found in Hodgkin's disease, where extensive irradiation 
increases the incidence of post-therapeutic acute leukemia (15). 
In some of these series, ANLL developed only after intensive 
combined chemotherapy and radiotherapy, suggesting an additive effect 
of the two modalities of treatment. It is probable that the combina¬ 
tion of radiation therapy and alkylating agent chemotherapy is more 
leukemogenic than either mode of therapy alone. 
Alkylating components are known to be immunosuppressive, leuke¬ 
mogenic, and carcinogenic in experimental animals and may exhibit these 
same characteristics in man (37, 65, 84, 86, 108). They probably exert 
their principal effects by accentuating immunosuppression and generating 
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chromosomal damage, as animal studies with melphalan have demonstrated 
(109). 
The first clear evidence that the alkylating agents are leukemo- 
genic has been provided by the accumulating case reports of the develop¬ 
ment of leukemia after therapy with these drugs. The multiplicity of 
drugs associated with secondary ANLL may suggest that any cytotoxic 
agent may be capable of leukemogenesis, however, the major conclusive 
evidence lies on the alkylating agents as a group since these drugs 
account for more than 85% of all reported cases. While cases of ANLL 
have followed therapy with antimetabolites, the vinca alkaloids and 
other classes of compounds, it appears that the incidence with these 
agents is much lower than with alkylators (17). 
The drugs most frequently implicated in reports of secondary 
ANLL are melphalan, chlorambucil, cyclophosphomide, thiotepa, and 
the nitrosoureas. A particularly high relative risk of secondary 
ANLL has until now been recorded for patients with multiple myeloma 
treated with melphalan (44, 47, 54) and for patients with lung 
cancer treated with busulfan (95). These two cytostatic agents are 
known to induce an often unpredictable, delayed, and severe marrow 
toxicity which could be of importance in leukemogenesis. In contrast 
to this, it has been assumed that treatment with more easily manageable 
agents, such as cyclophosphamide, is only to a lesser degree followed 
by leukemia (16, 95). 
The development of acute leukemia in patients with nonneoplastic 
disorders such as rheumatoid arthritis (42) and renal disease was a 
rare event until these patients began to receive treatment with 
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cytotoxic immunosuppressive chemotherapy (23, 52, 56, 97). Iatrogenic 
suppression of immunity with these agents in the course of management 
of patients with organ homografts is also associated with an increased 
frequency of malignant neoplasms (17, 69, 81, 98, 102). Recently 
Louie collected 31 such associations (56). One hundred and nine non- 
malignant diseases were treated by immunosuppressive drugs, and 94 
received no treatment. Acute myelogenous leukemia (AML) or one of 
its variants was observed in 28 treated patients (25.9%) whereas only 
2 developed in the untreated patients (3.2%). This difference was 
very significant and this high proportion of acute leukemia in 
treated patients appeared to provide convincing evidence of the 
leukemogenicity of these agents. 
It is known that the immunosuppressant action of these drugs 
compromises host resistance (70, 68). In these non-neoplastic 
disorders therapy has usually been given to suppress the production 
of autoantibodies. The interaction between chronic antigenic stimula¬ 
tion and immunodepression might predispose to malignant change. 
Suppression of the immunosurveillance system may allow a malignant 
clone of cells to emerge and multiply (14, 70, 106). This deficiency 
could also lead to the inability to resist a hypothetical virus-induced 
leukemia (5). 
Primary or secondary immunological deficiency states have been 
associated with markedly increased incidences of malignancies (68, 
25, 102, 106). Patients with primary immunodeficiency disorders 
such as X-linked agammaglobulinemia (Bruton type), and the DiGeorge 
syndrome have a sharply increased incidence of malignant neoplasms. 
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as high as 10,000 times that of the general age-matched population 
(59, 106). However, the spectrum of malignancies in immunosuppressed 
patients is qualitatively different from those receiving chronic 
alkylating agent therapy. Patients with congenital immunodeficiency 
states develop a variety of malignant conditions but most are lympho- 
reticular neoplasms, including acute lymphoblastic leukemia (81, 98). 
Patients who are immunosuppressed with antimetabolites and prednisone 
following organ transplantation usually develop epithelial carcinomas, 
(skin, lip, cervix, uterus) and malignant lymphomas; these have an 
unusual predilection to involve the alimentary tract (17, 70, 68). 
Except for a rare case report (87), ANLL has not been recognized as a 
complication of the immunosuppressive therapy given to transplant 
patients. These differences in the types of malignancies which develop 
following therapy suggest that complicating ANLL may be due to the 
known mutagenic actions of the alkylating agents. These observations 
suggest that the various alkylating agents have much higher leukemo- 
genic potential than other immunosuppressive drugs (17). 
Repeated or prolonged episodes of drug-induced marrow dysplasia 
may produce genetic damage to the hematopoietic stem cell and this 
may be another possible mechanism which can set the stage for leukemia. 
Chemical leukemogenesis after exposure to environmental and therapeutic 
agents has long been recognized. Arsenic, benzene, and toluene have 
been known to cause acute leukemia in those with a history of heavy 
exposure (2, 27, 49, 68). The population at high risk includes those 
involved in the leather and shoe manufacturing, dry cleaning, roto¬ 
gravure painting, and spray painting. In all cases exposure was 
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prolonged and heavy and the leukemia was nearly always preceded by a 
preleukemic syndrome (35). However, bone marrow depression is a more 
frequent finding in benzene poisoning than is the development of 
leukemia; the latter arrises in only a small proportion of the affected 
marrows (104). Chloramphenicol is another agent which frequently 
produced marrow damage and subsequent acute leukemia (18, 35). These 
situations are analogous to those seen in post-therapeutic leukemia 
with alkylating agents where there is evidence of extensive marrow 
damage prior to the development of leukemia (44, 68, 15, 17). These 
sequences of pancytopenia followed by leukemia have been described 
after marrow toxic reactions compounds, as well as after primary 
aplastic anemia (1, 12, 49). 
Patients with chromosomal abnormalities, pancytopenia, myelo¬ 
proliferative syndromes, and bone marrow dysplasia have been shown 
to be a great risk of developing acute leukemia (65). The prevalence 
of this disease in these patients suggests that marrow stem cell 
injury may be an important factor in the pathogenesis of leukemic 
transformation. Similar kinds of chromosomal breakage occur spon¬ 
taneously in congenital disorders such as Down's syndrome (105), 
Bloom's syndrome, Fanconi's anemia (32), ataxia telangiectasia and 
other inherited diseases (82, 28). These abnormalities, which are 
evident in both in vitro and in vivo cellular studies, have led to the 
speculation that disorganization in genetic material may lead to re¬ 
arrangements, point mutations, gene deletions, or duplications, at the 
biochemical level creating the conditions necessary for malignant 
growth. Similarly, marrow stem cells may be altered or damaged by the 
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effect of chemotherapy on DNA and on chromosomal karyotypes, eventually 
leading to the development of leukemia (20, 33). 
At least half of all reported cases of ANLL following cytotoxic 
agent therapy have had documented persistent cytopenia (17). Many 
of these patients have had documented "pre-leukemia" hypoplastic, 
hyperplastic, and/or sideroblastic marrows (44, 53). The incidence 
was evenly distributed among all disease subgroups. The incidence 
in the literature may actually have been higher since many case re¬ 
ports were brief and did not contain sufficient clinical information 
(17). Thus, persistent cytopenias and marrow aberrations have emerged 
as premonitory findings among patients who develop ANLL following 
prolonged chemotherapy (15, 68). 
It is not possible to state at which point in treatment the 
agent involved becomes leukemogenic. However, since leukemia may 
develop following continuous chemotherapy with an alkylating agent 
radiotherapy of various extents, or most commonly, following intensive 
treatment with extensive irradiation and polychemotherapy, it becomes 
necessary to develop a way to determine how long to continue therapy 
after remission, balancing the benefits of treatment against the risk 
of the development of ANLL. 
At present the optimal duration of therapy needed to achieve a 
chemotherapeutic cure of advanced ovarian carcinoma is unknown. 
In the past the plan had been to continue chemotherapy in these pa¬ 
tients indefinitely even if second look laparotomy procedures were 
negative (88). However, in view of the therapeutic hazard of leukemia 
development, the present objectives are directed toward the modification 
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of alkylating agent therapy and modification of the management of 
patients receiving this type of therapy. Proposed changes include 
more frequent use of second look procedures; clonogenic studies of 
ovarian tumor cells; frequent bone marrow analysis with culture studies; 
the sequential administration of alkylating agents; and the use of 
other drugs whenever possible. 
Second look procedures include laparoscopy and laparotomy. 
Second look laparoscopy with cytologic washings and biopsy of visible 
nodules, followed by second look laparotomy if all results of the 
laparoscopy are negative, has been advocated. Visible tumor or 
positive cytologic washings on laparoscopy would indicate continuation 
of chemotherapy and obviate the need for second look laparotomy, 
results on laparoscopy would be indications for further surgery 
before considering discontinuation of effective chemotherapy (71, 78, 
107) . 
The inclusion of in vitro clonogenic assays for predicting the 
response of tumors to chemotherapy might be useful. This assay is 
reported to have up to 62% predictive accuracy for complete and partial 
remission in these patients. This high accuracy rate in predicting 
clinical drug resistance suggests that it can be used to exclude 
drug trials which will not be clinically useful for tumor response 
but which will increase the patients' risk to overall toxicity (3). 
Serial bone marrow studies with bone marrow cultures may also 
help detect the risk of leukemia in these patients (96). However, 
morphological changes in the marrow are difficult to interpret. 
Many patients receiving cytotoxic drugs show evidence of dyserythropoiesis 
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and dysmyelopoiesis, though this usually disappears within a short 
time of stopping therapy (98). Furthermore, evolution of ANLL is 
unpredictable, a normal appearing study does not determine future 
behavior of the marrow. Many patients had normal appearing marrow 
analysis every few weeks or months before another bone marrow study 
showed advanced ANLL. 
Culturing bone marrow contents would be more indicative of 
recipient marrow damage, since this results in reduced colony-forming 
capacity (60). An attempt to monitor bone marrow function by this 
method would probably provide a good early warning system. At such 
a preleukemic time, withdrawal of alkylating therapy may allow the 
marrow to recover. 
It may also be possible to obtain good therapeutic results with 
somewhat less aggressive multi-drug therapy. The vast majority of 
patients developing ANLL distinctly benefited from therapy, with 
respect both to clinical remissions and prolongation of life, when 
compared with untreated patients. Patients with ovarian carcinoma, 
Hodgkin's disease, and multiple myeloma each accounted for approximately 
one-third of the cases having autopsy evidence of complete remission 
from the underlying disease (17). An intermittent schedule would 
allow time for recovery of both cellular and humoral immune function 
which had been suppressed by the agent employed and would allow the 
"rebound-overshoot" phenomenon of immune recovery to occur (39). 
Moreover, it has been suggested that with continuous chemotherapy 
one has the risk of suppressing those elements of the immune response 
necessary for tumor destruction (7, 94). 
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Another approach may be to substitute antimetabolites and other 
agents for alkylating agents whenever the choice is equal, since 
their oncogenic activity is of a lesser degree. With the advent of 
adriamycin and platinum as effective chemotherapeutic agents in the 
treatment of ovarian carcinoma, the use of alkylating agents will be 
decreased (112). 
In addition, since immunocompetence of the individual appears 
to be an important factor in the ultimate prognosis, it has been 
suggested that the immune response can be spared or even restored 
during therapy by administering nonspecific immunotherapy, such as 
BCG (34, 40). 
Faced with high numbers of reports of secondary ANLL, the chances 
of survival from the primary tumor must be weighed against benefit 
from potential leukemogenic drugs. As in our patients with ovarian 
carcinoma, the survival curve may only be slightly affected by cases 
of secondary ANLL. 
It is reassuring to know that the incidence of leukemia in 
patients treated for neoplasms or for non-neoplastic diseases with 
chemotherapy or combined chemotherapy and radiotherapy is still 
small and the number of patients enormously benefited by these types 
of therapy is very large (112). However, an analysis of the use of 
these drugs in conditions with a more favorable survival rate should 
take this leukemogenic potential into account. Although the risk of 
leukemogenesis in man may be small, these drugs should be used with 
caution in patients with indolent non-neoplastic diseases such as 
rheumatoid arthritis (17, 92). 
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Despite the dangers of bone marrow suppression and secondary 
malignancy, chemotherapy is still the treatment of choice in advanced 
malignancies. This estimated higher risk of ANLL may be acceptable 
with treatment of a disease with a relatively poor prognosis if such 
therapy results in improved survival. 
Ultimately, ovarian carcinoma remains a lethal disease with 
an insidious presentation and, therefore, not easily detectable during 
its earliest most curable stages. Consequently, the need for aggres¬ 
sive, extensive therapy remains in these patients. With a median 
survival in untreated cases of less than 10 months, the potential 
benefits of therapy clearly outweigh the risks. The estimated higher 
risk of leukemia development may be acceptable in the treatment of a 
disease with a relatively poor prognosis, if such therapy results in 
improved survival (76). As is the case with other malignancies, late 
death from leukemia after prolonged survival of cure from ovarian 
carcinoma is preferred to early death without remission. 
Analysis of the results from large prospective studies in coopera¬ 
tive chemotherapy groups will allow a more precise evaluation of the 
relative risk of secondary ANLL using single agents or cytostatic 
drugs in combinations. Long-term follow-up observations of patients 
in ongoing adjuvant chemotherapy trials should provide a clearer 
understanding of the risks and benefits of therapy with alkylating 
agents. Further studies are also needed to evaluate the carcinogenic 
effects that may result from interactions between different types of 




CLINICAL STAGING IN CARCINOMA OF THE OVARY 
FIGO CLASSIFICATION 
STAGE I: Growth limited to the ovaries. 
STAGE IA: Growth limited to one ovary; no ascites. 
(i) No tumor on the external surface; 
capsule intact. 
(ii) Tumor present on the external surface 
and/or capsule ruptured. 
STAGE IB: Growth limited to both ovaries; no ascites. 
(i) No tumor on the external surface; 
capsule intact. 
(ii) Tumor present on the external surface 
and/or capsule(s) ruptured. 
STAGE IC: Tumor either Stage IA or Stage IB, but with 
ascites* present or positive peritoneal 
washings. 
STAGE II: Growth involving one or both ovaries with pelvic extension. 
STAGE IIA: Extension and/or metastases to the uterus 
and/or tubes. 
STAGE IIB: Extension to other pelvic tissues. 
STAGE IIC: Tumor either Stage IIA or Stage IIB, but with 
ascites5' present or positive peritoneal washings. 
STAGE III: Growth involving one or both ovaries with intraperitoneal 
metastases outside the pelvis and/or positive retroperi¬ 
toneal nodes. Tumor limited to the true pelvis with 
histologically proven malignant extension to small bowel 
or omentum. 
STAGE IV: Growth involving one or both ovaries with distant metastases. 
If pleural effusion is present, there must be positive 
cytology to allot a case to Stage IV. Parenchymal liver 
metastases equals Stage IV. 
Special Category: Unexplored cases which are thought to be ovarian 
carcinoma. 
Ascites is peritoneal effusion which in the opinion of the 










5 100-500 1 
5 500-1,000 1 
5 1,000-1,500 0 
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36 400 14 2 0.50 14.28 5 
76 5455 NR 13 0.76 2 
43 374 10 1 2.00 10.00 3 
24 474 48 4 0.84 8.33 3 
67 553 NR 7 1.30 7 > 3 
1 > 2 
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